Developing new drugs to target a specific protein for advanced colon cancer treatment
Targeting SUMO1 degradation for advanced colon cancer therapy
This study is looking at new drugs that can help break down a protein linked to advanced colon cancer, with the hope of making treatments more effective, especially when combined with standard chemotherapy for patients facing this challenge.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10872292 on NIH RePORTER |
What this research studies
This research focuses on creating small-molecule drugs that can degrade a protein called SUMO1, which is linked to the resistance of advanced colon cancer to existing therapies. By using advanced techniques such as drug screening and 3D organoid models, the researchers aim to understand how these drugs can effectively target and eliminate cancer cells. The study will also explore the potential of combining these new drugs with standard chemotherapy to enhance treatment outcomes for patients with advanced colon cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced colon cancer, particularly those with organ invasion or liver metastasis.
Not a fit: Patients with early-stage colon cancer or those who do not have advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment option for patients with advanced colon cancer that is resistant to current therapies.
How similar studies have performed: While targeting SUMO1 is a novel approach, similar strategies targeting other proteins have shown promise in cancer treatment, indicating potential for success.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Bellail, Anita — Indiana University Indianapolis
- Study coordinator: Bellail, Anita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.